

INDEX

CHAPTER 1: INTRODUCTION:	7-23
1.1. Cancer:	7
1.2. Epidemiology:	7
1.3. Pathogenesis:	7
1.4. Diagnosis and management of breast cancer:	8
1.5. Current challenges for chemotherapy:	9
1.6. Recent scenario in the field of drug delivery:	9
1.7. Mesoporous silica nanoparticles:	10
1.8. History and mechanism of synthesis:	11
1.9. Surface modification of MSN:	13
1.9.1. Pore Gating	13
1.9.2. External surface modification of MSNs	13
1.9.2.1. Co-condensation process	14
1.9.2.2. Post synthesis strategy	14
1.10. Targeted drug delivery system using MSNs:	17
1.11. Toxicity, biocompatibility and biodegradation of MSNs:	17
1.12. Drug delivery by MSN:	18
1.13. References:	20
CHAPTER 2: LITERATURE REVIEW:	24-36
2.1. Utility of MSNs in the field of cancer:	24
2.2. Selection of active pharmaceutical ingredients:	27
2.2.1. Raloxifene hydrochloride (RLX):	27
2.2.2. Bexarotene (BXR):	28
2.3. Physicochemical properties of selected drugs:	28
2.3.1. RLX:	28
2.3.2. BXR:	30
2.4. Need for the current study:	31
2.5. References:	33
CHAPTER 3: AIMS AND OBJECTIVES	37-41
3.1. Aims	37
3.2. Objective:	37

3.3. Hypothesis:.....	41
3.4. Expected Outcomes:.....	41

CHAPTER 4: ANALYTICAL METHOD DEVELOPMENT AND VALIDATION.42-61

4.1. Introduction:.....	42
4.2. Materials and methods:	42
4.2.1. UV spectrophotometric method development.....	42
4.2.1.1. UV spectrophotometric method for RLX:.....	42
4.2.1.2. UV spectrophotometric method development for BXR:.....	43
4.2.2. RP-HPLC method development:.....	44
4.2.2.1. RP-HPLC method development RLX.....	44
4.2.2.2. RP-HPLC method development BXR.....	45
4.2.3. Bioanalytical method development:.....	46
4.2.3.1. Bioanalytical method development for RLX.....	46
4.2.3.2. Bioanalytical method development for BXR.....	48
4.3. Result and discussion.....	49
4.3.1. UV method development:.....	49
4.3.1.1. UV spectrophotometric method development for RLX:.....	49
4.3.1.2. UV spectrophotometric method development for BXR:.....	50
4.3.2. RP-HPLC method development:.....	51
4.3.2.1. RP-HPLC method development for RLX:.....	51
4.3.2.2. RP-HPLC method development for BXR.....	52
4.3.3. Bioanalytical method development.....	54
4.3.3.1. Bioanalytical method development for RLX.....	54
4.3.3.2. Bioanalytical method development for BXR.....	57
4.4. Summary:.....	61
4.5. References:.....	61

CHAPTER 5: RALOXIFENE..... 62-118

5.1. Introduction:.....	62
5.2. Materials and methods:	64
5.2.1. Chemicals and reagents:.....	64
5.2.2. Synthesis of MSN-41 and MSN-48 types of Nanocarriers:.....	65
5.2.2.1. Synthesis of MCM-41:.....	65
5.2.2.2. Synthesis of MCM-48:.....	65

5.2.2.3. Synthesis of amine coated MCM-41 and MCM-48 nanoparticles:	65
5.2.2.4. Synthesis of chitosan coated MCM-41 and MCM-48 nanoparticles:.....	65
5.2.2.5. Synthesis of folic acid-chitosan coated MCM-41 and MCM-48 nanoparticles:	66
5.2.3. Drug loading inside the nanopores:	66
5.2.4. Solid state evaluation of pristine and functionalized MSNs:	67
5.2.4.1. FT-IR analysis:.....	67
5.2.4.2. DSC analysis:.....	67
5.2.4.3. Wide angle x-ray diffraction (WXRd) analysis:	68
5.2.4.4. Small angle x-ray diffraction (SXRd) analysis:	68
5.2.4.5. Dynamic light scattering (DLS) analysis:	68
5.2.4.6. Nitrogen sorption analysis:	68
5.2.4.7. SEM and TEM analysis:	68
5.2.5. Elemental detection and Quantification of surface moiety:	69
5.2.5.1. Elemental detection:.....	69
5.2.5.2. Quantification of surface grafted moieties:.....	69
5.2.5.2.1. Quantification of amine group:	69
5.2.5.2.2. Quantification of other groups:	70
5.2.6. Tablet formation and evaluation:.....	70
5.2.7. In vitro release study:	71
5.2.7.1. In vitro dissolution study:	71
5.2.7.2. In vitro diffusion study:	72
5.2.8. In vitro cytotoxicity Study:.....	73
5.2.8.1. Caco-2 cell line:	73
5.2.8.2. MCF-7 cell line:	73
5.2.9. Cell permeability across Caco-2 cell monolayer:.....	74
5.2.10. In vitro cellular uptake study:	74
5.2.10.1. Synthesis of FITC labelled nanoparticles:	74
5.2.10.2. Intra cellular uptake study by confocal analysis:.....	75
5.2.10.3. Intracellular uptake study by flow cytometry:	75
5.2.11. Apoptosis assay	75
5.2.12 Hemolysis study:	76
5.2.13. In vivo pharmacokinetic study:	76
5.2.13.1. Pharmacokinetic study for oral formulation:	76
5.2.13.1.1. Experimental:	76

5.2.13.1.2. Sample preparation:.....	76
5.2.13.1.3. Pharmacokinetic parameters evaluation:.....	76
5.2.13.2. Pharmacokinetic study for parenteral formulation:	77
5.2.14. In vivo biodistribution study and histological examination	77
5.2.15. Statistical analysis.....	78
5.2.16. Stability study of prepared nanoparticles:	78
5.3. Result and discussion:	79
5.3.1. Solid state evaluation of MSNs:	79
5.3.1.1. FTIR:.....	79
5.3.1.2. DSC:.....	84
5.3.1.3. WXRd:	84
5.3.1.4. SXRD:.....	85
5.3.1.5. Nitrogen sorption study:	87
5.3.1.6. DLS study:	89
5.3.1.7. SEM and TEM analysis:	90
5.3.2. Estimation of %loading efficiency and entrapment efficiency:	93
5.3.3. %Grafting of different surface modifying agents.....	94
5.3.4. Formulation development:.....	98
5.3.5. In vitro dissolution study release study:	98
5.3.6. In vitro diffusion study release study:	100
5.3.7. In vitro cytotoxicity study on Caco-2 cell line for oral formulation:	102
5.3.8. In vitro cytotoxicity study on MCF-7 cell line for parenteral formulation:	102
5.3.9. In vitro permeability study for oral formulation:.....	105
5.3.10. Cellular uptake by confocal microscopy:	105
5.3.11. Cellular uptake by FACS.....	107
5.3.12. Apoptosis assay:	108
5.3.13. Haemolysis study:.....	109
5.3.14. In vivo pharmacokinetics study for oral formulation:	109
5.3.15 In vivo pharmacokinetics, biodistribution and histological examination study for parenteral formulation:	111
5.3.16. Stability study of synthesized nanoparticle:	113
5.4. Conclusion:.....	115
5.5. References:	116

CHAPTER 6: BEXAROTENE..... 119-167

6.1. Introduction:	119
6.2. Materials and methods:	121
6.2.1. Chemicals and reagents	121
6.2.2. Synthesis of MSN-41 and MSN-48 types of Nanocarriers:	122
6.2.2.1. Synthesis of large pore MCM-41	122
6.2.2.2. Synthesis of large pore MCM-48.....	122
6.2.2.3. Synthesis of amine coated MCM-41 and MCM-48 nanoparticles:	122
6.2.2.4. Synthesis of large pore hyaluronic acid coated MCM-41 and MCM-48 nanoparticles:	122
6.2.3. Drug loading inside the nanopores:	123
6.2.4. Solid state evaluation of pristine and functionalized MSNs.....	123
6.2.5. Elemental detection and Quantification of surface moiety:	124
6.2.5.1. Elemental detection:.....	124
6.2.5.2. Quantification of surface grafted moieties:.....	124
6.2.5.2.1. Quantification of amine group:	124
6.2.5.2.2. Quantification of other groups:	124
6.2.6. Formulation of laboratory mixture of BXR and evaluation:	124
6.2.7. In vitro release study:	125
6.2.7.1. In vitro dissolution study:	125
6.2.7.2. In vitro diffusion study:	126
6.2.8. In vitro cytotoxicity Study:	127
6.2.8.1. Caco-2 cell line:	127
6.2.8.2. MCF-7 cell line:	127
6.2.9. Cell permeability across Caco-2 cell monolayer:	128
6.2.10. In vitro cellular uptake study:	128
6.2.10.1. Synthesis of FITC labelled nanoparticles:	128
6.2.10.2. Intra cellular uptake study by confocal analysis:	129
6.2.10.3. Intracellular uptake study by flow cytometry:	129
6.2.11. Apoptosis assay	129
6.2.12. Hemolysis study:	130
6.2.13. In vivo pharmacokinetic study:	130
6.2.13.1. Pharmacokinetic study for oral formulation:	130
6.2.13.1.1. Experimental:	130
6.2.13.1.2. Sample preparation:.....	131
6.2.13.1.3. Pharmacokinetic parameters evaluation:.....	131

6.2.13.2. Pharmacokinetic study for parenteral formulation:	131
6.2.14. In vivo biodistribution study and histological examination	131
6.2.15. Statistical analysis.....	132
6.2.16. Stability study of prepared nanoparticles:	132
6.3. Result and discussion:	133
6.3.1. Solid state evaluation of MSNs:	133
6.3.1.1. FTIR:.....	133
6.3.1.2. DSC:.....	136
6.3.1.3. WXRd:	137
6.3.1.4. SXRD:.....	138
6.3.1.5. Nitrogen sorption study:	139
6.3.1.6. DLS study:	141
6.3.1.7. SEM and TEM analysis:	142
6.3.2. Estimation of %loading efficiency and entrapment efficiency:	143
6.3.3. %Grafting of different surface modifying agents.....	144
6.3.4. In vitro dissolution study release study:	147
6.3.5. In vitro diffusion study release study:	150
6.3.6. In vitro cytotoxicity study on Caco-2 cell line for oral formulation:	151
6.3.7. In vitro cytotoxicity study on MCF-7 cell line for parenteral formulation:	152
6.3.8. In vitro permeability study for oral formulation:.....	155
6.3.9. Cellular uptake by confocal microscopy:	155
6.3.10. Cellular uptake by FACS.....	157
6.3.11. Apoptosis assay:	158
6.3.12. Haemolysis study:.....	159
6.3.13. In vivo pharmacokinetics study for oral formulation:	159
6.3.14 In vivo pharmacokinetics and biodistribution study for parenteral formulation:	161
6.3.15. Stability study of synthesized nanoparticle:	163
6.4. Conclusion:.....	165
6.5. References:	166
 CHAPTER 7: SUMMARY:.....	 168-173
7.1. Summary for RLX.....	168
7.2. Summary for BXR	171
 LIST OF PUBLICATIONS:	 174-175